Zinc this is nicely written but a few suggested alternate understandings of immune responses. The immune system responds to antigens in a manner that is independent of protein structure on the virus because it happens only after something called antigen processing and presentation. Viral proteins are captured by antigen presenting cells (APC) and cut into small bits and pieces that are either 9-10 amino acids long (class i MHC) or 18-24 amino acids long (class II MHC). When T cells and subsequently B cells are stimulated, it is now fragments. The size and folding of these fragments determine what clones of antibodies are made and how those react with the full size protein on the virus. This is best described as editing of clones based on how your professional antigen presentations mimic a functional site (fusion) on the viral protein when it unfolds and prepares for entry. This unfolding takes but a fraction of a second and therefore requires antibodies that are at high titer and are able to block the full functional unfolding required for cell entry.
Quick now let's jump to the next threat. The Boubon virus is here in Anerica now and killing Kansans. Call the national guard.
Seriously this is a bad actor, orthomyxovirus that is spread by ticks. Watch for news over the next years summer tick season and this will pop up.
It helps to have the ability to actually make the product, both a history of doing so and infrastructure. It was not lobbyists it was and is capacity. Duh
Is a meeting like this even allowed under disclosure laws. I would steer clear of any unknowns as this smacks of special access for a specific group. And for what? It's a junk publication who cares
Two things. Yes likely to create a defined pathway but not clear that will expedite or create tape. Second, the path will be shorter/easier for a subunit approach compared to live viral constructs.
Bunch of bull here. You have little to no idea of what is requested and why. Nor do you have any idea of what Herculean tasks are required to start such trials. But sure 'hasty' is what you say, how about desperately trying to make a difference in a real world problem and they think they have a solution. I know the guys at GSK and they are not the bogeyman. They have both good products and good intentions and you should hope they like NVAX as they are more likely than anyone else to partner or buy. Your bs contributes zip to the real world in which this need will play out.
The one many are now referring to as pandemic (beyond MRSA) is a strain of uropathogenic E. coli that is multidrug resistant called ST 131. Nasty and exactly what this is for.
lots of upside from here still. Second ph3 indication has read out coming early in 2015 and would double market size estimates. The ph3 lead in study is done and indicates high probability of ph 3 second success as well. This will replace standard of care.
It is my largest holding in fact (17k shares) and one I think will work out in 2015. That said there is a lot of pressure on the stock that is unrelated to the actual stage of development and near term milestones. Many don't think they will file in 2015 as stated, or that FDA will accept the filing as AA. I think it will fly and that they will prevail in both the clinic and in the courts with patent issues. Don't love the stock but really love the technology. The FDA hurt them badly this last year and a half, and I am keenly aware of this issue as well in which guidance is one thing, follow through an entirely different thing. I saw that up close recently and it was not fun. They will not turn down the AA application.
easy 50 now with one ph3 indication in the books, if the second comes through (and it will) the target mentioned last week (not me) at 80 seems possible as well.
Today is a really good time to wish all well for the holidays. And if anyone listened when I mentioned TTPH over the last several months, that one just exploded with positive ph 3 news after the close today. (3k @9). Today up 3.19, after hours news has it up another 6.50 (now at 39.50). Expect to see 40 tomorrow and buy outs will come at above 50 early in 2015.
booom ya love me them biotechs